Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.57 |
| ▸ | PDE4A | P27815 | 3/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.57 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6032076 | 0.88 | PDE4B (0.60) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL3453181 | 0.86 | PDE4B (0.78) | PDE4BPDE4DPDE4APDE4CSMN1; SMN2 | |
| SCHEMBL6031273 | 0.84 | PDE4B (0.57) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL2324507 | 0.82 | PDE4B (0.58) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL6031965 | 0.82 | PDE4B (0.53) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6032100 | 0.81 | PDE4B (0.53) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6031774 | 0.81 | PDE4B (0.55) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6030991 | 0.80 | PDE4A (0.53) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6031269 | 0.80 | PDE4B (0.51) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6031803 | 0.80 | PDE4B (0.52) | PDE4BPDE4DPDE4APDE4CPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167001-A1 | Pyridazinone-derivatives as pde4 inhibitors | ALTANA PHARMA AG (DE) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167001-A1 | Pyridazinone-derivatives as pde4 inhibitors | PDE4A, PDE3A, PDE4B | PDE4B 3/4885PDE4D 8/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.